Rapamycin for Prevention of Chronic Graft-Versus-Host Disease

Status Terminated

Clinical Trial Summary

The objective of this study is to evaluate feasibility, toxicity and efficacy of using Rapamycin to prevent chronic graft-versus-host-disease (GVHD) during and after the tacrolimus taper in recipients of allogeneic stem cell transplant.

Our hypothesis is that the T cells that can cause chronic GVHD are suppressed but not eliminated by calcineurin inhibitors. Therefore, when the calcineurin inhibitors are discontinued, the T cells may get activated and result in GVHD. Rapamycin on the other hand will allow anergy formation and thus when discontinued, T cells should not get activated. The schedule is designed to have therapeutic rapamycin levels as the tacrolimus is discontinued. Rapamycin will be continued as a single agent for additional 4 weeks and be tapered off in two weeks.

Clinical Trial Description

n/a

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00623012
Study type	Interventional
Source	Yale University
Contact
Status	Terminated
Phase	Phase 1/Phase 2
Start date	February 2008
Completion date	August 2013

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03357159` - Anti T-lymphocyte Immunoglobulin With Post Transplant Cyclophosphamide to Prevent GVHD Post Allogeneic Transplantation	Phase 2
Completed	`NCT00003270` - Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer	Phase 2
Terminated	`NCT02877082` - Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients	Phase 2
Recruiting	`NCT01385124` - Cannabidiol for Graft Versus Host Disease (GVHD) Prophylaxis in Allogeneic Stem Cell Transplantation	Phase 1/Phase 2
Withdrawn	`NCT01616680` - Brentuximab Vedotin in Treating Patients With Steroid-Resistant Acute Graft-Versus-Host Disease	Phase 2
Recruiting	`NCT01810926` - T&B Depletion Non Malignant	Phase 2
Completed	`NCT01379209` - Intravenous Administration of RGI-2001 in Patient Undergoing Allogenic Hematopoietic Stem Cell Transplantation (AHSCT)	Phase 1/Phase 2
Completed	`NCT01233921` - Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer	N/A
Recruiting	`NCT00986557` - T-Lymphocyte Infusion or Standard Therapy in Treating Patients at Risk of Cytomegalovirus Infection After a Donor Stem Cell Transplant	Phase 2
Enrolling by invitation	`NCT00972660` - Safety and Efficacy Study of Allogenic Mesenchymal Stem Cells to Treat Extensive Chronic Graft Versus Host Disease	Phase 2
Terminated	`NCT00555048` - Alemtuzumab, Busulfan, and Cyclophosphamide Followed By a Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer	Phase 1/Phase 2
Terminated	`NCT00373815` - Everolimus in Combination With Cyclosporine A and Prednisolone for the Treatment of Graft Versus Host Disease	Phase 1
Terminated	`NCT00608517` - Treatment of Single or Double Umbilical Cord Trans + Graft-versus-host Disease (GVHD) Prophylaxis w/ Tacrolimus & Mycophenolate Mofetil	N/A
Completed	`NCT00056875` - Recombinant Human Keratinocyte Growth Factor in Unrelated and Related Transplants	Phase 1/Phase 2
Recruiting	`NCT05808985` - Intestinal Microbiome-based Research for the Prevention of Acute GVHD	Phase 2
Completed	`NCT00813618` - Study of MEDI 507 in the Treatment of Pediatric Patients	Phase 1
Completed	`NCT00003398` - Bone Marrow Transplantation in Treating Patients With Hematologic Cancer	Phase 4
Terminated	`NCT00005641` - Removal of T Cells to Prevent Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation	Phase 2
Completed	`NCT02663622` - Phase II Trial of Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft-Versus-Host Disease (GVHD) Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-002)	Phase 2
Completed	`NCT00577278` - A Phase II Study of Allo-HCT for B-Cell NHL Using Zevalin, Fludarabine and Melphalan	Phase 2